MedTrace Logo

Efficacy of Anisodamine Hydrobromide Combined With Low-molecular-weight Heparin in the Treatment of Patients With Sepsis

NCT05634057 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 782

Last updated 2025-05-21

No results posted yet for this study

Summary

The study aimed to investigate the effectiveness of anisodamine hydrobromide combined with heparin in the treatment of patients with critical infection, in the hope that the therapy will provide alternatives to the treatment of patients with critical infection.

Conditions

Interventions

DRUG

Anisodamine hydrobromide combined with heparin

The anisodamine hydrobromide combined with heparin treatment group is on the basis of conventional treatment.

Sponsors & Collaborators

  • Chen Ying

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
110 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-25
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05634057 on ClinicalTrials.gov